Quick Answer
Cyclerion Therapeutics, Inc. reported Total Revenue of $2.07 million for fiscal year 2025.
Cyclerion Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $2.07M +3.7% |
$2.00M | $0.00 -100.0% |
$297.0K -92.5% |
$3.94M +71.7% |
$2.30M -49.1% |
| Revenue (ASC 606) | — | — | — | — | — | $2.30M -49.1% |
| Net Income | -$3.53M -15.4% |
-$3.06M +41.9% |
-$5.26M +88.1% |
-$44.08M +14.7% |
-$51.65M +33.6% |
-$77.80M +36.8% |
| Diluted EPS | -$1.11 +8.3% |
-$1.21 +46.2% |
-$2.25 +88.9% |
-$20.28 -1436.4% |
-$1.32 | — |
| Total Assets | $9.98M +4.3% |
$9.57M -28.4% |
$13.37M -26.0% |
$18.08M -69.5% |
$59.33M -48.6% |
$115.38M -38.1% |
| Cash and Equivalents | $3.24M +0.2% |
$3.23M -57.3% |
$7.57M -43.4% |
$13.38M -75.2% |
$53.96M -0.8% |
$54.40M -42.7% |
| Stockholders Equity | $9.09M +2.7% |
$8.85M -21.6% |
$11.29M +8.0% |
$10.45M -78.3% |
$48.25M -18.9% |
$59.49M -39.1% |
| R&D Expense | $959.0K +235.3% |
$286.0K -81.1% |
$1.51M -74.7% |
$5.98M -84.1% |
$37.64M -33.3% |
$56.41M -40.7% |
| Operating Income | -$4.97M -37.1% |
-$3.63M +72.0% |
-$12.95M +30.1% |
-$18.54M +66.4% |
-$55.20M +32.1% |
-$81.27M +35.0% |
| Shares Outstanding | 3.82M +50.1% |
2.55M +2.9% |
2.47M +13.7% |
2.18M -95.0% |
43.41M +27.5% |
34.05M +23.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $875.0K | +351.0% | +840.9% |
| Revenue (ASC 606) | September 30, 2020 | $400.0K | -71.4% | -46.6% |
| Net Income | September 30, 2025 | -$976.0K | -35.0% | -201.2% |
| Diluted EPS | September 30, 2025 | -$0.30 | -3.4% | -172.7% |
| Total Assets | September 30, 2025 | $10.41M | +17.0% | +11.2% |
| Cash and Equivalents | September 30, 2025 | $4.57M | +59.1% | +52.0% |
| Stockholders Equity | September 30, 2025 | $9.54M | +16.3% | +11.3% |
| R&D Expense | September 30, 2025 | $348.0K | +329.6% | +521.4% |
| Operating Income | September 30, 2025 | -$1.01M | +10.8% | +39.8% |
| Shares Outstanding | September 30, 2025 | 3.70M | +46.0% | +20.1% |
- Cyclerion Therapeutics, Inc. reported Total Revenue of $2.07 million for fiscal year 2025.
- Cyclerion Therapeutics, Inc. showed an increase of +3.7% in Total Revenue compared to the prior fiscal year.
- Cyclerion Therapeutics, Inc. reported Revenue (ASC 606) of $2.30 million for fiscal year 2020.
- Cyclerion Therapeutics, Inc. showed a decrease of -49.1% in Revenue (ASC 606) compared to the prior fiscal year.
- Cyclerion Therapeutics, Inc. reported Net Income of -$3.53 million for fiscal year 2025.
- Cyclerion Therapeutics, Inc. showed a decrease of -15.4% in Net Income compared to the prior fiscal year.
- Cyclerion Therapeutics, Inc. reported Diluted EPS of $1.11 per share (loss) for fiscal year 2025.
- Cyclerion Therapeutics, Inc. showed an increase of +8.3% in Diluted EPS compared to the prior fiscal year.
- Cyclerion Therapeutics, Inc. reported Total Assets of $9.98 million for fiscal year 2025.
- Cyclerion Therapeutics, Inc. showed an increase of +4.3% in Total Assets compared to the prior fiscal year.
- Cyclerion Therapeutics, Inc. reported Cash and Equivalents of $3.24 million for fiscal year 2025.
- Cyclerion Therapeutics, Inc. showed an increase of +0.2% in Cash and Equivalents compared to the prior fiscal year.
- Cyclerion Therapeutics, Inc. reported Stockholders Equity of $9.09 million for fiscal year 2025.
- Cyclerion Therapeutics, Inc. showed an increase of +2.7% in Stockholders Equity compared to the prior fiscal year.
- Cyclerion Therapeutics, Inc. reported R&D Expense of $959.0 thousand for fiscal year 2025.
- Cyclerion Therapeutics, Inc. showed an increase of +235.3% in R&D Expense compared to the prior fiscal year.
- Cyclerion Therapeutics, Inc. reported Operating Income of -$4.97 million for fiscal year 2025.
- Cyclerion Therapeutics, Inc. showed a decrease of -37.1% in Operating Income compared to the prior fiscal year.
- Cyclerion Therapeutics, Inc. reported Shares Outstanding of 3.82 million shares for fiscal year 2025.
- Cyclerion Therapeutics, Inc. showed an increase of +50.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: